| Factor Information | |
|---|---|
| Data ID | 2811 |
| Factor | NGAL levels throughout the first 6 extracorporeal membrane oxygenation days |
| Description | Neutrophil gelatinase-associated lipocalin levels remained higher among patients on continuous venovenous hemofiltration than others throughout the examined extracorporeal membrane oxygenation period (p=0.0007). |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | diagnosis and prognosis |
| Objective | To evaluate diagnostic and prognostic significance of neutrophil gelatinase-associated lipocalin during extracorporeal membrane oxygenation in children with congenital heart disease. |
| p Value | 0.0007 |
| Conclusion | Neutrophil gelatinase-associated lipocalin levels remained higher among patients on continuous venovenous hemofiltration than others throughout the examined extracorporeal membrane oxygenation period (p =0.0007). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 626 |
| CHD Type | isolated CHD |
| CHD Subtype | AVC/TA/TOF/HLHS/MS/AC, VSD/UVH, HAA |
| Reference | |
|---|---|
| PMID | 21057360 |
| Year | 2012 |
| Title | Neutrophil gelatinase-associated lipocalin levels during extracorporeal membrane oxygenation in critically ill children with congenital heart disease: preliminary experience |
| Sample | ||
|---|---|---|
| Population | infants, children | |
| Source | Database | |
| Region | Rome, Italy | |
| Method | Prospective observational study. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Patients on CVVH (continuous venovenous hemofiltration) (Treatment) | Patients Not on CVVH(continuous venovenous hemofiltration) (Control) |
| Number | 3 | 7 |
| Age | 31 (7–5008) days | 13 (9–3056) days |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | N/A | N/A |
